TransGenex Nanobiotech, Inc. (TGN), is a Florida-based nanobiotechnology company incorporated in 2004.
Our Mission is to discover, develop and commercialize nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases.
June 27, 2015
June 18, 2015
Florida Institute Funds Tampa-based TransGenex Nanobiotech, Inc.
October 14, 2014
Transgenex co-founder Dr. Subhra Mohapatra receives USF’s Excellence in Innovation Award.
September 16, 2014
TransGenex Receives $224,999in SBIR Phase-I Contract from National Cancer Institute to further develop and commercialize a biopsy-derived tumoroid platform for personalizing cancer treatment.
TransGenex Receives a second $224,999in SBIR Phase-I Contract from National Cancer Institute to develop new drugs targeting cancer stem cells.